Welcome to our dedicated page for Majestic Ideal SEC filings (Ticker: MJID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Majestic Ideal Holdings Ltd (MJID) aggregates the company’s regulatory reports from its period as a Nasdaq-listed foreign private issuer and through its transition to Ping An Biomedical Co., Ltd with the new ticker PASW. As a foreign private issuer, the company files annual reports on Form 20-F and furnishes current information on Form 6-K under the Securities Exchange Act of 1934.
Among the key filings are the Form F-1 registration statement referenced in a Form 6-K, which underpinned the company’s initial public offering of ordinary shares on the Nasdaq Capital Market, and subsequent Form 6-K reports that describe the underwriting agreement, adoption of governance documents such as the code of business conduct and ethics and committee charters, and the company’s insider trading policy. These documents help investors understand the company’s capital raising and governance framework at the time of its IPO.
The filings page also includes Form 6-K reports covering unaudited first half 2025 financial results, along with Inline XBRL instance and taxonomy extension documents. These materials provide structured financial data for the company’s interim reporting period. Additional Form 6-Ks document corporate actions such as the extraordinary general meeting of shareholders, the approval of the change of company name to Ping An Biomedical Co., Ltd, and the anticipated change in ticker symbol from MJID to PASW.
Further filings detail board and management changes, including resignations and appointments of chief executive officers, the chairperson of the board, the chief financial officer, and independent directors, with the company stating that these resignations were for personal reasons and not due to disagreements with the company or board. On Stock Titan, users can access these filings as they appear on EDGAR and use AI-powered summaries to quickly understand long documents such as the registration statement, Form 20-F annual report, and Form 6-K current reports, as well as review insider trading policies and other governance-related exhibits.
Ping An Biomedical Co., Ltd. CEO Liu Pijun has filed an initial statement of beneficial ownership. The filing shows that 12,250,000 Class A Ordinary Shares are held indirectly through INSPIRETECH LTD, reflecting a substantial position associated with the chief executive but does not report any recent share purchases or sales.
Ping An Biomedical Co., Ltd. filed a Form 3 identifying Liu Xianzhi (XZL) as a director and reporting person. The filing does not list any insider purchase, sale, or other equity transaction, and shows no derivative positions or holding entries in this report.
Ping An Biomedical Co., Ltd. CFO Yang Hongli filed an initial Form 3 as an officer of the company. The filing lists no reportable transactions, and the transaction summary shows zero buys, sells, exercises, gifts, tax withholdings, or restructurings, with derivative positions also not reported.
Ping An Biomedical Co., Ltd. reported that shareholders approved all five resolutions at the 2026 annual general meeting in Hong Kong. The vote authorizes a major overhaul of the company’s share capital structure, including the creation of high-vote Class B shares and a future share consolidation.
Authorised share capital will become US$312,500, divided into 4,900,000,000 Class A ordinary shares and 100,000,000 Class B ordinary shares, each with a par value of US$0.0000625. Shareholders also adopted a second amended and restated memorandum and articles of association tied to these capital changes.
The meeting further approved a targeted transaction with major shareholder INSPIRETECH LTD, allowing the company to repurchase 12,250,000 Class A shares from INSPIRETECH in exchange for issuing 12,250,000 Class B shares, leaving INSPIRETECH’s total share count unchanged but shifting part of its holding into high-vote stock. A large-scale share consolidation may be implemented within one year at the board’s discretion, with the company’s governing documents to be amended to reflect the consolidation once effected.
Ping An Biomedical Co., Ltd. filed an initial insider ownership report for director Liu Qingxian. The filing shows indirect ownership of 599,400 Class A Ordinary Shares as of the reported date, held through SONIC FLASH LIMITED, which is attributed as the ownership vehicle. This Form 3 does not report any new share purchases or sales, only existing holdings.
Ping An Biomedical Co., Ltd. filed an initial insider ownership report for director Gao Jifeng
Ping An Biomedical has called its Annual General Meeting for March 18, 2026 in Hong Kong. Shareholders will vote on major capital and governance changes.
Key items include amending authorised share capital to US$312,500 divided into 4,900,000,000 Class A ordinary shares and 100,000,000 Class B ordinary shares, both with a par value of US$0.0000625. The company seeks to adopt a Second Amended and Restated Memorandum and Articles of Association, replacing the existing governing documents.
Shareholders are also asked to authorise a Share Repurchase and Issue in which the board may repurchase 12,250,000 Class A shares from INSPIRETECH LTD, funded by issuing 12,250,000 new Class B shares to INSPIRETECH. Additional proposals cover a share consolidation and related conforming amendments. Holders of ordinary shares at the March 3, 2026 record date may vote in person or by proxy, and the board unanimously recommends voting in favour of all proposals.
Ping An Biomedical Co., Ltd. has filed to register up to 13,611,800 ordinary shares for resale by an existing shareholder on Nasdaq under the symbol PASW. The company will not receive any proceeds from these sales, which are solely for the selling shareholder’s account.
Ping An operates an apparel supply-chain services business in China through its PRC subsidiary New Brand but is pursuing a major strategic expansion into biopharmaceuticals via planned investments in Future Biotechnology Group. The prospectus highlights extensive risks tied to operating in China, evolving PRC oversight of overseas listings and data security, potential CSRC filing requirements, HFCA Act-related audit risks, and possible cash-transfer constraints from China and Hong Kong.
Additional risks include ambitious performance targets and potentially dilutive share issuances for the Future Biotechnology deal, as well as Nasdaq minimum bid-price and low-price rules that could lead to suspension or delisting if compliance is not regained.
Ping An Biomedical Co., Ltd. entered into securities purchase agreements with accredited investors for a private placement of 100,000,000 ordinary shares at $0.04 per share, for total gross proceeds of $4,000,000. The transaction is expected to close within three business days of February 9, 2026, subject to customary conditions.
The shares are being sold in an unregistered offering relying on Section 4(a)(2), Regulation D, and Regulation S exemptions. Investors must be accredited or non‑U.S. persons, and the ordinary shares will carry transfer restrictions and restrictive legends because they are not registered under the U.S. Securities Act.